EU/3/18/1979

Table of contents

About

Please note that this product was withdrawn from the Union Register of orphan medicinal products in March 2020 on request of the Sponsor.

On 22 February 2018, orphan designation (EU/3/18/1979) was granted by the European Commission to Bayer AG, Germany, for human monoclonal IgG2 antibody against tissue factor pathway inhibitor (also known as BAY 1093884) for the treatment of haemophilia A.

Key facts

Active substance
Human monoclonal IgG2 antibody against tissue factor pathway inhibitor
Disease / condition
Treatment of haemophilia A
Date of first decision
22/02/2018
Outcome
Withdrawn
EU designation number
EU/3/18/1979

Sponsor's contact details

Bayer AG
51368 Leverkusen
Germany
Tel. +49 30 300 139 003
E-mail: clinical-trials-contact@bayer.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating
Average
1 rating